J M Raboud

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. ncbi request reprint Estimating the effect of treatment on quality of life in the presence of missing data due to drop-out and death
    J M Raboud
    Department of Health Care and Epidemiology, University of British Columbia, Canada
    Qual Life Res 7:487-94. 1998
  2. pmc Comparison of costs of strategies for measuring levels of human immunodeficiency virus type 1 RNA in plasma by using Amplicor and Ultra Direct assays
    J M Raboud
    Canadian HIV Trials Network, University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Microbiol 36:3369-71. 1998
  3. ncbi request reprint Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team
    J M Raboud
    Department of Health Care and Epidemiology, University of British Columbia, Vancouver, Canada
    J Acquir Immune Defic Syndr 22:260-6. 1999
  4. ncbi request reprint Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals
    J M Raboud
    University of British Columbia, St Paul s Hospital, Vancouver, Canada
    Antivir Ther 2:237-47. 1997
  5. ncbi request reprint Symptomatic and health status outcomes in the Canadian randomized MAC treatment trial (CTN010). Canadian HIV Trials Network Protocol 010 Study Group
    J Singer
    Canadian HIV Trials Network, St Paul s Hospital, Vancouver, BC
    Int J STD AIDS 11:212-9. 2000
  6. doi request reprint Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice
    Tony Antoniou
    University of Toronto, Toronto, Ontario, Canada, Maple Leaf Medical Clinical, Toronto, Ontario, Canada
    J Int Assoc Physicians AIDS Care (Chic) 9:382-9. 2010
  7. pmc Violence in the emergency department: a survey of health care workers
    C M Fernandes
    Department of Emergency Medicine, St Paul s Hospital, Vancouver, BC
    CMAJ 161:1245-8. 1999

Collaborators

Detail Information

Publications7

  1. ncbi request reprint Estimating the effect of treatment on quality of life in the presence of missing data due to drop-out and death
    J M Raboud
    Department of Health Care and Epidemiology, University of British Columbia, Canada
    Qual Life Res 7:487-94. 1998
    ..To obtain a valid assessment of the effect of treatment on quality of life, the experience of the patients who died or dropped out of the study must be considered...
  2. pmc Comparison of costs of strategies for measuring levels of human immunodeficiency virus type 1 RNA in plasma by using Amplicor and Ultra Direct assays
    J M Raboud
    Canadian HIV Trials Network, University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Microbiol 36:3369-71. 1998
    ..For patients with weak virologic responses, small savings could be obtained by using Amplicor and retesting only samples with values below 500 copies/ml with Ultra Direct...
  3. ncbi request reprint Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team
    J M Raboud
    Department of Health Care and Epidemiology, University of British Columbia, Vancouver, Canada
    J Acquir Immune Defic Syndr 22:260-6. 1999
    ..To determine whether baseline pVL is predictive of virologic response during the study periods...
  4. ncbi request reprint Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals
    J M Raboud
    University of British Columbia, St Paul s Hospital, Vancouver, Canada
    Antivir Ther 2:237-47. 1997
    ..No statistical differences were detected between doses of didanosine with respect to survival or progression to a new ADI or death. Furthermore, there was no statistical difference in the frequency of ADC between treatment arms...
  5. ncbi request reprint Symptomatic and health status outcomes in the Canadian randomized MAC treatment trial (CTN010). Canadian HIV Trials Network Protocol 010 Study Group
    J Singer
    Canadian HIV Trials Network, St Paul s Hospital, Vancouver, BC
    Int J STD AIDS 11:212-9. 2000
    ..The 3-drug arm is superior to the 4-drug arm in terms of impact on MAC-associated symptoms, functional status and other aspects of health status...
  6. doi request reprint Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice
    Tony Antoniou
    University of Toronto, Toronto, Ontario, Canada, Maple Leaf Medical Clinical, Toronto, Ontario, Canada
    J Int Assoc Physicians AIDS Care (Chic) 9:382-9. 2010
    ..Objective: To compare the effectiveness and safety of ritonavir (TPV/r)- and darunavir/ritonavir (DRV/ r)-based therapies in treatment-experienced patients (n = 38 and 47, respectively)...
  7. pmc Violence in the emergency department: a survey of health care workers
    C M Fernandes
    Department of Emergency Medicine, St Paul s Hospital, Vancouver, BC
    CMAJ 161:1245-8. 1999
    ....